Table 1 Clinical and biological characteristics of preBLL patients include in this study

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | Site of involvement | | | | | | Laboratory data | | |  | Immunophenotypic data | | | | | | | | |  |
| Pt. | Sex | Age (y) | FAB | BM(%) | Mass | CNS | LN | H/S | Other Site | LDH (U/L) | UA (mg/dL) | WBC (/mm3) | TLS | CD19 | CD10 | CD20 | sIgM | cμ | κ/λ | TDT | CD34 | HLA-DR | Outcome |
| 1 | F | 1.5 | L2 | 90 | - | + | - | - |  | >9,000 | 14.26 | 35,300 | - | + | + | - | - | + | - | + | - | + | Relapse 5m DOD 11m |
| 2 | M | 9 | n.c. | 29 | - | - | + | - |  | 598 | 3.58 | 3,400 | - | + | + | + | - | - | - | + | - | + | ANED 77m+ |
| 3 | F | 2 | L3 | 82 | - | - | + | + |  | 2,152 | 3.23 | 75,800 | - | + | + | - | - | - | - | + | - | + | ANED 30m+ |
| 4 | F | 8.5 | L2 | 84 | - | - | - | - |  | >8,600 | 7.98 | 11,360 | + | + | + | - | - | - | - | - | - | + | ANED 41m+ |
| 5 | M | 3.7 | n.c. | 70 | + | + | + | + | Kidney, pancreas, intestinal | >8,600 | 14.46 | 30,480 | + | + | + | + | - | - | - | - | - | + | ANED 45m+ |
| 6 | M | 12.8 | L2 | 78 | - | - | + | + |  | >8,600 | 11.04 | 199,450 | - | + | + | - | - | - | - | + | - | + | Relapse 7m DOD 8m |
| 7 | F | 10 | L3 | 67 | - | - | - | - |  | >8,600 | 2.80 | 22,880 | - | + | + | - | - | - | - | - | - | + | ANED 19m+ |
| 8 | F | 5.2 | L2 | 60 | - | - | - | + |  | 2,934 | 1.08 | 710 | - | + | + | + | - | - | - | + | + | + | ANED 30m+ |
| 9 | M | 8.1 | L3 | 90 | - | - | + | + |  | 2,821 | 3.91 | 16,700 | - | + | + | - | - | - | - | + | - | + | Relapse 19m DOD 32m |

*Pt.* Patients, *F* female, *M* male, *y* years, *m* month, *BM* bone marrow, *CNS* central nervous system, *LN* lymphadenopathy, *H/S* liver/spleen, *LDH* lactate dehydrogenase, *UA* uric acid, *WBC* white bone marrow, *TLS* tumor lysis syndrome, *n.c.* not classifiable, *s* surface, *κ/λ* intracytoplasmic, *TdT* terminal deoxynucleotidyl transferase, *ANED* alive with no evidence of disease, *DOD* dead of disease, + positive (intracytoplasmic:>10%，extracytoplasmic: >20%), - negative

Figure 1. The clinical course of nine patients with preBLL. One square, one month; blue square, protocols of mature B-cell neoplasms; green square, ALL-type chemotherapy; grey square, individualized treatment; red dot, relapse; black dot, death; orange arrow, maintenance therapy; black arrow, follow-up; *R*, rituximab; *C*, CAR-T therapy